Academic Journals Database
Disseminating quality controlled scientific knowledge

Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes

ADD TO MY LIST
 
Author(s): Pascale Fouqueray

Journal: Journal of Diabetes & Metabolism
ISSN 2155-6156

Volume: 2;
Issue: 4;
Date: 2011;
Original page

Keywords: Imeglimin | Glimin | Novel oral anti-diabetic | Type 2 diabetes | Type 2 diabetes pharmacological treatment | Three defects type 2 diabetes | Pre-clinical findings

ABSTRACT
Study background: The objective of this collated research paper is to highlight the anti-diabetic effects and mode of action of imeglimin, the first in a new tetrahydrotriazine-containing class of oral anti-diabetic agents: the glimins. Imeglimin acts on both insulin resistant organs (liver and muscle) and pancreatic β-cells (insulin secretion in response to glucose and protection against apoptosis). Methods: The aim of the investigations reported here is to present data on the mode of action of imeglimin and its anti-diabetic effects, demonstrating that it represents a promising treatment for type 2 diabetes by acting on the three key pathological defects of the disease, namely excessive hepatic glucose production, impaired peripheral glucose uptake by skeletal muscle, and insufficient insulin secretion. Results: Imeglimin significantly lowered fasting plasma glucose concentrations in a dose-dependent manner in STZ rats. HbA1c was significantly reduced (P
Why do you need a reservation system?      Affiliate Program